Blueprint Medicines' primary revenue driver is Ayvakit, approved for various forms of Systemic Mastocytosis (SM) and showing strong growth, with 2024 revenues at $479m. The company projects Ayvakit to ...
Throughout the last three months, 10 analysts have evaluated Blueprint Medicines (NASDAQ:BPMC), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the ...
Sanofi's deal to acquire Blueprint was announced on June 2nd ,for an initial amount of $9.1bn, or $129 per share. Sanoi will acquire Blueprint's approved drug for mastocytosis Aykavit, which earned ...
Throughout the last three months, 14 analysts have evaluated Blueprint Medicines (NASDAQ:BPMC), offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback